Sun Pharmaceutical Industries Limited carries what we call a hope premium: an average business trading at an ambitious price.
The price is expensive. You pay 36.6× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 14% yearly growth; analysts expect 16%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202359
88
2023202420252026
All-time high
96
Jul 2024
All-time low
41
Oct 2025
Average rank
72
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
13
19
34
46
Price/Earnings
25
40
46
50
Price/Book
21
37
45
56
Dividend Yield
59
53
50
45
Value (overall)
20
28
33
43
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.